Comparative Pharmacology
Head-to-head clinical analysis: AMINOCAPROIC versus CYKLOKAPRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOCAPROIC versus CYKLOKAPRON.
AMINOCAPROIC vs CYKLOKAPRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibition of plasminogen activation and, to a lesser extent, noncompetitive inhibition of plasmin, thereby preventing fibrinolysis and promoting clot stability.
Competitive inhibition of plasminogen activation, reducing fibrinolysis by blocking the binding of plasminogen to fibrin.
4-5 g orally or intravenously as a loading dose, followed by 1 g/hour continuous infusion or 1 g every 4-6 hours orally. Maximum dose 30 g/day.
1 g (10 mL) IV over 5-10 minutes every 6-8 hours; or 25-50 mg/kg/day IV divided every 6-8 hours. Oral: 1-1.5 g 3-4 times daily.
None Documented
None Documented
Terminal elimination half-life: 2 hours (normal renal function); prolonged to 4–10 hours in renal impairment. Clinically, dosing interval must be adjusted in renal dysfunction to avoid accumulation.
Clinical Note
moderateAminocaproic acid + Tretinoin
"Aminocaproic acid may increase the thrombogenic activities of Tretinoin."
Terminal elimination half-life: 2-3 hours (renal impairment extends to 10-20 hours).
Primarily renal (>95%) as unchanged drug via glomerular filtration and tubular secretion. Less than 1% biliary/fecal.
Renal: >95% as unchanged drug via glomerular filtration; minimal biliary/fecal (<5%).
Category C
Category C
Antifibrinolytic
Antifibrinolytic